NCT03462719 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 106
- group Id
- BG001
- value
- 105
- group Id
- BG002
- value
- 211
- units
- Participants
- groups
- description
- Participants received ibrutinib 420 milligrams (mg) orally once daily for 3 cycles (each cycle is of 28 days) followed by the combination of ibrutinib 420 mg and venetoclax 400 mg orally once daily for 12 cycles (including a 5-week venetoclax dose ramp up starting in cycle 4). Participants who subsequently developed independent review committee (IRC)-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.
- id
- BG000
- title
- Treatment Arm A (Ibrutinib + Venetoclax)
- description
- Participants received chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight orally once daily on Days 1 and 15 of Cycles 1 to 6 in combination with obinutuzumab 1000 mgs intravenously (IV) once daily on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 to 6 (each cycle is of 28 days). Participants who subsequently developed IRC-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.
- id
- BG001
- title
- Treatment Arm B (Chlorambucil + Obinutuzumab)
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.02
- value
- 71
- group Id
- BG001
- spread
- 6.16
- value
- 72
- group Id
- BG002
- spread
- 7.01
- value
- 71.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 47
- group Id
- BG001
- value
- 42
- group Id
- BG002
- value
- 89
- title
- Female
- measurements
- group Id
- BG000
- value
- 59
- group Id
- BG001
- value
- 63
- group Id
- BG002
- value
- 122
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 101
- group Id
- BG001
- value
- 99
- group Id
- BG002
- value
- 200
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 101
- group Id
- BG001
- value
- 101
- group Id
- BG002
- value
- 202
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 9
- title
- BELGIUM
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 17
- title
- CANADA
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 22
- title
- CZECH REPUBLIC
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 12
- title
- DENMARK
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- title
- FRANCE
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 18
- title
- ISRAEL
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 7
- title
- NETHERLANDS
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 22
- title
- POLAND
- categories
- measurements
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 39
- title
- RUSSIAN FEDERATION
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 19
- title
- SPAIN
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- SWEDEN
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 21
- title
- TURKEY
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 106
- group Id
- BG001
- value
- 105
- group Id
- BG002
- value
- 211
- units
- Participants
- groups
- description
- Participants received ibrutinib 420 milligrams (mg) orally once daily for 3 cycles (each cycle is of 28 days) followed by the combination of ibrutinib 420 mg and venetoclax 400 mg orally once daily for 12 cycles (including a 5-week venetoclax dose ramp up starting in cycle 4). Participants who subsequently developed independent review committee (IRC)-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.
- id
- BG000
- title
- Treatment Arm A (Ibrutinib + Venetoclax)
- description
- Participants received chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight orally once daily on Days 1 and 15 of Cycles 1 to 6 in combination with obinutuzumab 1000 mgs intravenously (IV) once daily on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 to 6 (each cycle is of 28 days). Participants who subsequently developed IRC-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.
- id
- BG001
- title
- Treatment Arm B (Chlorambucil + Obinutuzumab)
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 8.02
- value
- 71
- group Id
- BG001
- spread
- 6.16
- value
- 72
- group Id
- BG002
- spread
- 7.01
- value
- 71.5
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 47
- group Id
- BG001
- value
- 42
- group Id
- BG002
- value
- 89
- title
- Female
- measurements
- group Id
- BG000
- value
- 59
- group Id
- BG001
- value
- 63
- group Id
- BG002
- value
- 122
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 101
- group Id
- BG001
- value
- 99
- group Id
- BG002
- value
- 200
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 101
- group Id
- BG001
- value
- 101
- group Id
- BG002
- value
- 202
- title
- White
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 9
- title
- BELGIUM
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 17
- title
- CANADA
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 22
- title
- CZECH REPUBLIC
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 12
- title
- DENMARK
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 7
- title
- FRANCE
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 18
- title
- ISRAEL
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 7
- title
- NETHERLANDS
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 22
- title
- POLAND
- categories
- measurements
- group Id
- BG000
- value
- 23
- group Id
- BG001
- value
- 16
- group Id
- BG002
- value
- 39
- title
- RUSSIAN FEDERATION
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 19
- title
- SPAIN
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- title
- SWEDEN
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 21
- title
- TURKEY
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Region of Enrollment
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle